Abstract
We optimized the protocol for thyroid ablation in living mice using radioactive iodine (RAI) and a low-iodine diet (LID). To examine the effect of LID on thyroid ablation, mice were randomly divided into 4 groups: Vehicle, 131I 2.775 MBq, 131I 5.55 MBq, and LID + 131I 2.775 MBq. The LID group was fed a LID for up to 7 days and then mice in the 131I 2.775, 131I 5.55, and LID + 131I 2.775 MBq groups were intravenously administrated with 131I, respectively. Scintigraphy imaging with 99mTc pertechnetate was performed once in 2 weeks for 4 weeks. After establishment of athyroid mice, control or athyroid mice were injected with human anaplastic thyroid cancer cells co-expressing sodium iodine symporter and enhanced firefly luciferase (ARO/NF) to evaluate RAI uptake. Scintigraphy imaging with 99mTc pertechnetate was performed with ARO/NF tumor-bearing mice. Scintigraphy imaging showed decreased thyroid uptake in the LID + 131I 2.775 MBq group compared to other groups. Scintigraphy images showed that tumor uptake was statically higher in athyroid mice than in control mice. These data suggest that these optimized conditions for thyroid ablation could be helpful to establish an in vivo mouse model.
Highlights
Carcinoma of the thyroid gland is the most common endocrine malignancy (95%), representing approximately 1% of all malignancies in Western countries[1,2,3]
low-iodine diet (LID) are widely used to deplete body iodine pools, which increases the availability of radioactive iodine to NIS-expressing tissues[27,28,29,30]
The American Thyroid Association (ATA) recommends an LID defined by an intake of
Summary
Carcinoma of the thyroid gland is the most common endocrine malignancy (95%), representing approximately 1% of all malignancies in Western countries[1,2,3]. 131I is an effective therapeutic modality for thyroid cancers that express sodium iodide symporter (NIS), a substantial percentage of metastatic thyroid carcinomas do not express adequate levels of the protein and are categorized as radioiodine refractory thyroid cancers. These cancers do not or respond poorly to chemotherapy and radiotherapy, and show poor prognosis compared to differentiated thyroid cancers[9,10,11,12]. Factors, including total thyroid volume, body iodine pool, and thyroid-stimulating hormone (TSH) levels[19,20] Even though it provides many benefits, reports of 131I thyroid ablation are rare for athyroid mouse models, and 131I thyroid ablation has not yet been optimized[21,22,23]. The current study established an athyroid mouse model using 131I administration and optimized the 131I thyroid ablation protocol in this mouse model
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
